The #AskBio team recently returned from the #IAPRD2024 World Congress in Lisbon. While on site, we engaged with various experts from the movement disorder community. Our experience was capped off by a packed house for an oral presentation by our VP of Global Clinical Development, Amber Van Laar, who delivered 18-month PD safety, preliminary efficacy, and imaging data for our Phase 1b clinical trial for AB-1005, an investigational #genetherapy for treating patients with Parkinson’s disease. (For more information about the AB-1005 Phase 1b Trial, visit clinicaltrials.gov (NCT#04167540). #Parkinsonsdisease
Exciting news for patients with Parkinson's Disease! Congratulations!
Creating Effective Therapies for Chronic Incurable Diseases
2moAmazing data and the culmination of decades of failing up. Sincere Congratulations